BridgeBio Oncology Therapeutics
BBOT | NASDAQ
$1.98
-$0.16 (-7.48%)
At close: Nov 16, 2026, 4:00 PM ET
$2.01
+$0.03 (+1.52%)
After-hours:
Nov 16, 2026, 7:00 PM ET
BridgeBio Oncology Therapeutics Company Profile
Company profile explainedCompany Profile
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Pedro J. Beltran | Chief Executive Officer and Director |
| Idan Elmelech | Chief Operating Officer |
| Aaron Chan | Vice President of Legal |
| Bin Wang | Senior Vice President of Drug Discovery |
| Daniel Watson | Senior Vice President of Chemistry, Manufacturing & Controls |
| Frank McCormick | Co-Founder, Non-Executive Director & Chair of the Advisory Board |
| Marc Cobo | VP of Finance & Controller |
| Neil Kumar | Executive Chairman |
| Rui Xu | Senior Vice President of Drug Discovery |
| Yong Ben | Chief Medical & Development Officer |
BridgeBio Oncology Therapeutics
| Country | United States |
| IPO Date | Aug 12, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Pedro J. Beltran |
Contact Details
256 E. Grand Avenue South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | BBOT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001869105 |
| CUSIP Number | 107924102 |
| ISIN Number | US1079241022 |
| SIC Code | 6770 |
Recent News
- 10 months ago / seekingalpha.comBridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript
Add to Watchlist
Select watchlists to add or remove BBOT